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The use of corticosteroids and nebulised bronchodilators in bronchial asthma (BA) is a major 
concern during the COVID-19 pandemic. Inhaled corticosteroid (ICS) is the recommended 
treatment for all levels of BA severity, while oral corticosteroid (OCS) is used in severe asthma 
and acute exacerbation of BA (AEBA).1 Because corticosteroid is an immunosuppressant, BA 
patients on corticosteroid treatment are theoretically at a higher risk of contracting COVID-19 
and may suffer more severe disease. Nebulisation of bronchodilators is a frequent treatment 
modality for patients attending an emergency department for AEBA because of a common 
perception that it is more effective and faster in symptom relief. However, nebulisation may 
cause dispersion of SARS-CoV-2 into the surrounding environment, putting other patients and 
